NO981864L - Upl ° sningsmetoder - Google Patents

Upl ° sningsmetoder

Info

Publication number
NO981864L
NO981864L NO981864A NO981864A NO981864L NO 981864 L NO981864 L NO 981864L NO 981864 A NO981864 A NO 981864A NO 981864 A NO981864 A NO 981864A NO 981864 L NO981864 L NO 981864L
Authority
NO
Norway
Prior art keywords
sningsmetoder
upl
proteins
biologically active
active compounds
Prior art date
Application number
NO981864A
Other languages
Norwegian (no)
Other versions
NO981864D0 (en
Inventor
Roger Randal Charles New
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of NO981864D0 publication Critical patent/NO981864D0/en
Publication of NO981864L publication Critical patent/NO981864L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

For bedre metoder for oppløsning av biologisk aktive forbindelser, for eksempel proteiner i et hydrofobt oppløsningsmiddel.For better methods of dissolving biologically active compounds, for example, proteins in a hydrophobic solvent.

NO981864A 1995-10-25 1998-04-24 Upl ° sningsmetoder NO981864L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9521805.3A GB9521805D0 (en) 1995-10-25 1995-10-25 Solubilisation methods
PCT/GB1996/002609 WO1997015289A1 (en) 1995-10-25 1996-10-25 Solubilisation methods

Publications (2)

Publication Number Publication Date
NO981864D0 NO981864D0 (en) 1998-04-24
NO981864L true NO981864L (en) 1998-06-24

Family

ID=10782854

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981864A NO981864L (en) 1995-10-25 1998-04-24 Upl ° sningsmetoder

Country Status (12)

Country Link
EP (1) EP0857061A1 (en)
JP (1) JP2000502990A (en)
KR (1) KR19990067028A (en)
CN (1) CN1202818A (en)
AU (1) AU704292B2 (en)
BR (1) BR9611343A (en)
CA (1) CA2235487A1 (en)
GB (1) GB9521805D0 (en)
NO (1) NO981864L (en)
NZ (1) NZ320442A (en)
WO (1) WO1997015289A1 (en)
ZA (1) ZA969016B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605709D0 (en) * 1996-03-19 1996-05-22 Cortecs Ltd Method
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DE602007009377D1 (en) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
JP5351884B2 (en) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド Suspension preparation and use of insulin secretagogue peptide
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (en) 2015-06-03 2024-05-08 I2O Therapeutics Inc Implant placement systems
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012115A1 (en) * 1978-12-04 1980-06-11 Ciba-Geigy Ag Pharmaceutical compositions for topical treatment of virus infections
US4411882A (en) * 1978-12-21 1983-10-25 Sandoz Ltd. Galenical compositions

Also Published As

Publication number Publication date
BR9611343A (en) 1999-12-28
EP0857061A1 (en) 1998-08-12
NO981864D0 (en) 1998-04-24
ZA969016B (en) 1998-04-28
CN1202818A (en) 1998-12-23
AU704292B2 (en) 1999-04-15
GB9521805D0 (en) 1996-01-03
JP2000502990A (en) 2000-03-14
KR19990067028A (en) 1999-08-16
CA2235487A1 (en) 1997-05-01
AU7317896A (en) 1997-05-15
NZ320442A (en) 1999-10-28
WO1997015289A1 (en) 1997-05-01

Similar Documents

Publication Publication Date Title
NO981864L (en) Upl ° sningsmetoder
DE69104777D1 (en) Oral drug forms of biologically active proteins.
DK0730406T3 (en) Microcapsules containing suspensions of biologically active compounds
BR0207776A (en) Sterol derivative, liposomes comprising the same, method of loading said liposomes and use thereof
HUP9603305A2 (en) [(pyrrolyl-carbonyl)-amino]-naphtalene derivatives, capable for improving biological availability of biologically active compounds
ATE203025T1 (en) REVERSE TURN MIMETICS AND RELATED METHOD
DK0600866T3 (en) Preparations and Methods for Identifying Biologically Active Molecules
ES2088160T3 (en) CHEMICAL FORMULATION AND PROCESS.
EA199800288A1 (en) DERIVATIVES 5-O-DEOZOMINIL-6-O-METHYLERITRONOLID A, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION FOR OBTAINING BIOLOGICAL ACTIVE PRODUCTS
DK366889A (en) peptide
TR199701567T1 (en) Rapamis t�revler.
ES2125233T3 (en) TREATMENT OF HUMAN RETROVIRAL INFECTIONS WITH 2 ', 3'-DIDESOXYINOSINE.
ES2176456T3 (en) PROCEDURE FOR THE PREPARATION OF AN HIV PROTEASA INHIBITING COMPOUND.
ES2148259T3 (en) PRO-PROFARMACOS, ITS PRODUCTION AND USE.
NO982567D0 (en) Improved Hydrogenolysis of 2,4,6,8,10,12-Hexaazatetracyclo (5.5.0.05.903.11) dodecane
DE3863366D1 (en) ANTIBIOTIC VERMISPORIN, METHOD FOR THE PRODUCTION THEREOF AND THE SAME PHARMACEUTICAL COMPOSITION CONTAINING IT AS AN ACTIVE ANTIBACTERIAL ACTIVE SUBSTANCE.
FI961437A (en) Active substance delivery system
ES2107284T3 (en) NEW N-PIRIDIL-CARBOXAMIDES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
SE9501285L (en) Process for producing biologically active proteins
AU4515996A (en) Methods for increasing the bioavailability of biological active agents
NO902626D0 (en) PROCEDURE FOR STABILIZING BIOLOGICALLY ACTIVE COMPOUNDS IMMOBILIZED AT SOLID PHASES.
DE69616944D1 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I AS AN ACTIVE SUBSTANCE AGAINST HEART HYPERTROPHY
NO884721D0 (en) PROCEDURE FOR MANUFACTURING BIOLOGICALLY ACTIVE COMPONENTS.
EE9800193A (en) Biologically active benzothiazolone ethanamines
TR199701298T1 (en) Tetralins.